GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets.
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.
7 Micro-Cap Stocks That Could Majorly Surprise Investors Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look.
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Lantheus Holdings, Inc. (
NASDAQ: LNTH ) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
